In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery

• Published in: PLoS computational biology Vol. 16; no. 5; p. e1007926
• Main Authors: Meaney, Cameron, Rhebergen, Sander, Kohandel, Mohammad
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 28.05.2020; Public Library of Science (PLoS)
• Subjects: Analysis; Angiogenesis; Angiogenesis inhibitors; Anoxia; Antiangiogenic agents; Antiangiogenics; Applied mathematics; Biology and Life Sciences; Blood; Chemical compounds; Chemotherapy; Clinical trials; Combination drug therapy; Cytotoxicity; Dosage and administration; Drug delivery; Drug delivery systems; Drug dosages; Drug targeting; Drug therapy; Drugs; Glioblastoma; Growth factors; Hypoxia; Mathematical models; Medicine and Health Sciences; Methods; Nanomedicine; Nanoparticles; Physical Sciences; Prodrugs; Research and Analysis Methods; Selectivity; Treatment resistance; Tumors; Canada; Waterloo Ontario Canada
• ISSN: 1553-7358; 1553-734X; 1553-7358
• DOI: 10.1371/journal.pcbi.1007926

Tumour hypoxia is a well-studied phenomenon with implications in cancer progression, treatment resistance, and patient survival. While a clear adverse prognosticator, hypoxia is also a theoretically ideal target for guided drug delivery. This idea has lead to the development of hypoxia-activated prodrugs (HAPs): a class of chemotherapeutics which remain inactive in the body until metabolized within hypoxic regions. In theory, these drugs have the potential for increased tumour selectivity and have therefore been the focus of numerous preclinical studies. Unfortunately, HAPs have had mixed results in clinical trials, necessitating further study in order to harness their therapeutic potential. One possible avenue for the improvement of HAPs is through the selective application of anti angiogenic agents (AAs) to improve drug delivery. Such techniques have been used in combination with other conventional chemotherapeutics to great effect in many studies. A further benefit is theoretically achieved through nanocell administration of the combination, though this idea has not been the subject of any experimental or mathematical studies to date. In the following, a mathematical model is outlined and used to compare the predicted efficacies of separate vs. nanocell administration for AAs and HAPs in tumours. The model is experimentally motivated, both in mathematical form and parameter values. Preliminary results of the model are highlighted throughout which qualitatively agree with existing experimental evidence. The novel prediction of our model is an improvement in the efficacy of AA/HAP combination therapies when administered through nanocells as opposed to separately. While this study specifically models treatment on glioblastoma, similar analyses could be performed for other vascularized tumours, making the results potentially applicable to a range of tumour types.